Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 95, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2023.129490
Keywords
Mizoribine; Prodrugs; Immunosuppressive agents; Inosine-monophosphate dehydrogenase
Categories
Ask authors/readers for more resources
Researchers prepared three different types of prodrugs of Mizoribine, and found that the ester derivatives effectively inhibited the secretion of specific immune molecules and prolonged graft survival. The combination therapy of these prodrugs with tacrolimus also showed a synergistic effect in vivo.
Mizoribine is a well-known immunosuppressive drug, based on a nucleoside scaffold, that targets inosinemonophosphate dehydrogenase (IMPDH). In an effort to increase its in vivo efficacy, three different types of prodrugs (a phosphoramidate prodrug, a lipophilic ester derivative and an amino acid conjugate) were prepared. Screening of these prodrugs in a rapid whole blood assay revealed that the two ester-based mizoribine prodrugs potently inhibited interleukin 2 secretion. Moreover, these prodrugs were able to prolong graft survival, when evaluated in a mouse model of cardiac allograft transplantation. Strikingly, a combination therapy of these mizoribine prodrugs with tacrolimus had a synergistic in vivo effect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available